B.Riley Financial Maintains a Buy Rating on Arbutus Biopharma (ABUS)
In a report issued on January 8, Mayank Mamtani from B.Riley Financial maintained a Buy rating on Arbutus Biopharma (ABUS), with a price target of $8.00. The company’s shares closed last Tuesday at $4.11.
According to TipRanks.com, Mamtani is a 5-star analyst with an average return of 33.9% and a 57.6% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Spectrum Pharmaceuticals, and Madrigal Pharmaceuticals.
Arbutus Biopharma has an analyst consensus of Strong Buy, with a price target consensus of $7.67.
See today’s analyst top recommended stocks >>
Arbutus Biopharma’s market cap is currently $366.8M and has a P/E ratio of -3.10. The company has a Price to Book ratio of -6.71.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Arbutus Biopharma Corp. engages in discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus infection. The company is headquartered in Burnaby, Canada.